Galera Therapeutics (GRTX) Competitors $0.02 0.00 (-1.20%) As of 04/25/2025 03:38 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock GRTX vs. CYCN, BFRI, ADXN, MYNZ, RNAZ, OMGA, INDP, AIM, APLM, and SLXNShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Cyclerion Therapeutics (CYCN), Biofrontera (BFRI), Addex Therapeutics (ADXN), Mainz Biomed (MYNZ), TransCode Therapeutics (RNAZ), Omega Therapeutics (OMGA), Indaptus Therapeutics (INDP), AIM ImmunoTech (AIM), Apollomics (APLM), and Silexion Therapeutics (SLXN). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Cyclerion Therapeutics Biofrontera Addex Therapeutics Mainz Biomed TransCode Therapeutics Omega Therapeutics Indaptus Therapeutics AIM ImmunoTech Apollomics Silexion Therapeutics Cyclerion Therapeutics (NASDAQ:CYCN) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking. Does the MarketBeat Community believe in CYCN or GRTX? Galera Therapeutics received 16 more outperform votes than Cyclerion Therapeutics when rated by MarketBeat users. However, 58.62% of users gave Cyclerion Therapeutics an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote. CompanyUnderperformOutperformCyclerion TherapeuticsOutperform Votes3458.62% Underperform Votes2441.38% Galera TherapeuticsOutperform Votes5054.35% Underperform Votes4245.65% Do insiders and institutionals believe in CYCN or GRTX? 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 36.1% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is CYCN or GRTX more profitable? Galera Therapeutics' return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion TherapeuticsN/A -55.32% -48.35% Galera Therapeutics N/A N/A -99.34% Which has more risk and volatility, CYCN or GRTX? Cyclerion Therapeutics has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Does the media prefer CYCN or GRTX? In the previous week, Cyclerion Therapeutics had 1 more articles in the media than Galera Therapeutics. MarketBeat recorded 1 mentions for Cyclerion Therapeutics and 0 mentions for Galera Therapeutics. Cyclerion Therapeutics' average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score. Company Overall Sentiment Cyclerion Therapeutics Neutral Galera Therapeutics Neutral Which has higher earnings and valuation, CYCN or GRTX? Cyclerion Therapeutics has higher revenue and earnings than Galera Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$2M4.40-$5.26M-$1.22-2.66Galera TherapeuticsN/AN/A-$59.08M-$0.35-0.07 SummaryCyclerion Therapeutics beats Galera Therapeutics on 8 of the 12 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.86M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.31%P/E Ratio-0.077.1422.1418.40Price / SalesN/A238.89389.70101.30Price / CashN/A65.6738.2034.62Price / Book-0.016.266.664.18Net Income-$59.08M$142.48M$3.21B$247.71M7 Day PerformanceN/A7.90%6.21%6.61%1 Month PerformanceN/A-4.23%-2.83%-2.22%1 Year PerformanceN/A-2.70%16.43%4.67% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.02-1.2%N/A-88.1%$1.86MN/A-0.0730CYCNCyclerion Therapeutics1.3648 of 5 stars$2.70-1.8%N/A+3.5%$7.32M$2M-2.2130Positive NewsGap DownBFRIBiofrontera2.2463 of 5 stars$0.81-4.7%$7.00+764.2%-52.1%$7.19M$37.32M-0.3670Positive NewsADXNAddex Therapeutics1.8903 of 5 stars$6.75-10.0%$30.00+344.4%-49.6%$7.16M$556,045.00-19.8530News CoverageGap DownMYNZMainz Biomed1.7072 of 5 stars$3.07-4.7%$14.00+356.0%-89.7%$7.12M$893,991.00-0.0530Positive NewsRNAZTransCode Therapeutics2.048 of 5 stars$0.30+10.1%$10.00+3,233.3%-99.9%$7.00MN/A0.009Gap UpHigh Trading VolumeOMGAOmega Therapeutics1.847 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.7%$6.92M$8.10M-0.09120Gap UpINDPIndaptus Therapeutics2.1678 of 5 stars$0.46-3.1%$8.50+1,728.4%-78.4%$6.71MN/A-0.276News CoverageNegative NewsAIMAIM ImmunoTech1.8835 of 5 stars$0.09-22.3%$2.75+2,908.8%-77.5%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeAPLMApollomics1.6355 of 5 stars$5.91-0.7%$200.00+3,284.1%-85.8%$6.57M$1.22M0.0045Gap UpSLXNSilexion TherapeuticsN/A$0.72-3.8%$5.00+592.8%N/A$6.52MN/A0.00N/ANews CoveragePositive NewsGap Up Related Companies and Tools Related Companies CYCN Competitors BFRI Competitors ADXN Competitors MYNZ Competitors RNAZ Competitors OMGA Competitors INDP Competitors AIM Competitors APLM Competitors SLXN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRTX Stock Free GRTX Stock Alerts